DelveInsight’s “Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast–2034” report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.

 

Explore the intricate details of the Nontuberculous Mycobacterial Infections Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Nontuberculous Mycobacterial Infections Market Forecast. Click here to stay ahead in healthcare innovation @ Nontuberculous Mycobacterial Infections Market Size

 

Key Takeaways from the Non-Tuberculous Mycobacterial Infections Market Report

• The Non-Tuberculous Mycobacterial Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• Based on DelveInsight’s epidemiology model, the total number of diagnosed prevalent cases of Nontuberculous Mycobacterial Infections in the US was around 108,000 in 2023, with an anticipated increase during the forecast period (2024–2034) due to various contributing factors.
• In 2023, NTM Infections in the US showed a higher prevalence in females compared to males. Females represented about 68% of the total diagnosed prevalent cases of Nontuberculous Mycobacterial Infections, while males accounted for around 32%.
• In 2023, M. avium was the most common species responsible for Nontuberculous Mycobacterial Infections in the US, accounting for nearly 76 thousand diagnosed prevalent cases. It was followed by M. abscessus with around 14 thousand cases, and other species like M. kansasii and M. xenopi, which contributed to approximately 18 thousand cases.
• In 2023, the US had about 86 thousand diagnosed prevalent cases of Nontuberculous Mycobacterial Infections of the pulmonary type and approximately 22 thousand cases of the extrapulmonary type
• As per Shanmugam et al., about 1·5 million people died from TB, and nearly 10 million people fall ill with Mtb infection worldwide, of which only 6·4 million were diagnosed and officially reported
• Among the 7MM countries. The most prevalent cases of Non- Tuberculous Mycobacterial infections were recorded in the United States.
• The leading Non- Tuberculous Mycobacterial Infections Companies such as Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others
• Promising Non- Tuberculous Mycobacterial Infections Therapies such as SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others

 

Navigate the complexities of the Nontuberculous Mycobacterial Infections Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Nontuberculous Mycobacterial Infections Market Forecast. Click here to get more insights @ Nontuberculous Mycobacterial Infections Treatment Market

 

Non-Tuberculous Mycobacterial Infections Epidemiology Segmentation in the 7MM

• Total Prevalence of Non- Tuberculous Mycobacterial Infections
• Prevalent Cases of Non- Tuberculous Mycobacterial Infections by severity
• Gender-specific Prevalence of Non- Tuberculous Mycobacterial Infections
• Diagnosed Cases of Episodic and Chronic Non- Tuberculous Mycobacterial Infections

 

Download the report to understand which factors are driving Non-Tuberculous Mycobacterial Infections epidemiology trends @ Non-Tuberculous Mycobacterial Infections Prevalence

 

Nontuberculous Mycobacterial Infections Marketed Drugs

• ARIKAYCE (amikacin liposome inhalation suspension): Insmed

ARIKAYCE is the first FDA-approved therapy indicated for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed’s proprietary PULMOVANCE liposomal technology enables the delivery of amikacin directly to the lungs, where lung macrophages take it up, targeting the site of infection. This approach prolongs the release of amikacin in the lungs while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira Nebulizer System manufactured by PARI Pharma GmbH.

 

Nontuberculous Mycobacterial Infections Emerging Drugs

• Epetraborole: AN2 Therapeutics

Epetraborole (EBO), developed by AN2 Therapeutics, is a novel, once-daily, orally administered investigational treatment for patients with chronic NTM lung disease. Epetraborole is a boron-containing small molecule inhibitor of bacterial leucyl-tRNA synthetase, or LeuRS, an enzyme that catalyzes the attachment of leucine to transfer RNA, or tRNA, molecules, an essential step in protein synthesis. Epetraborole forms a complex with a tRNALEU molecule, trapping the terminal ribonucleotide of tRNALEU in the editing site of the enzyme, which prevents the synthetic site from attaching leucine to tRNALEU thus shutting down tRNA leucylation and leading to a block in protein synthesis. Currently, the drug is in Phase II/III of clinical development for the treatment of patients with NTM lung disease. AN2 Therapeutics intends to expand the indication targeted by epetraborole by pursuing development in other mycobacterial diseases, including treatment-naïve MAC lung disease. AN2 Therapeutics also intends to conduct trials in which they plan to incorporate epetraborole as part of first-line combination treatment for treatment-naive patients with NTM lung disease and M. abscessus lung infections.

 

• MNKD-101 (Clofazimine Inhalation Suspension): Mannkind Corporation

MNKD-101, a nebulized formulation of clofazimine, is being developed for the treatment of severe chronic and recurrent pulmonary infections, including NTM lung disease. An orally inhaled formulation of clofazimine is anticipated to offer several clinical advantages over the current solid oral dosage form of this drug. MNKD-101 has been designated as both an orphan drug and a qualified infectious disease product by the US FDA for the treatment of pulmonary NTM infections. Mannkind is also assessing the feasibility of developing a dry-powder formulation of clofazimine using Mannkind’s technosphere formulation technology. MNKD-101 is designated with fast-track designation by the US FDA for the treatment of NTM lung infections. Mannkind intends to commence a Phase III registration study of MNKD-101 in the US in the second quarter of 2024.

 

• SPR720 (Fobrepodacin): Spero Therapeutics

SPR720, developed by Spero Therapeutics, is a broad-spectrum oral antibiotic designed to treat NTM pulmonary disease. SPR720 employs a novel mechanism and has no known cross-resistance with marketed antibiotics. SPR720 has demonstrated a broad spectrum of activity in preclinical studies against the most common organisms causing NTM infections, including M. avium complex, or MAC, M. kansasii, and M. abscessus. SPR720 is applicable to both nonrefractory and refractory patients.

 

Unlock insights into the Nontuberculous Mycobacterial Infections Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Nontuberculous Mycobacterial Infections Market Forecast. Click here @ Nontuberculous Mycobacterial Infections Market Drivers and Barriers

 

Non- Tuberculous Mycobacterial Infections Therapies and Companies

• SPR720: Spero Therapeutics
• Molgramostim: Savara Pharmaceuticals
• Thiolanox (Nitric Oxide): Mallinckrodt Inc.
• NUZYRA (omadacycline): Paratek Pharmaceuticals Inc.
• CYT 107: Revimmune

 

Scope of the Non- Tuberculous Mycobacterial Infections Market Report

• Study Period: 2020–2034
• Coverage: 7MM
• Non-Tuberculous Mycobacterial Infections Companies: Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others
• Non-Tuberculous Mycobacterial Infections Therapies: SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others
• Non-Tuberculous Mycobacterial Infections Therapeutic Assessment: Non- Tuberculous Mycobacterial Infections current marketed and Non- Tuberculous Mycobacterial Infections emerging therapies
• Non-Tuberculous Mycobacterial Infections Market Dynamics: Non- Tuberculous Mycobacterial Infections market drivers and Non- Tuberculous Mycobacterial Infections market barriers
• Non- Tuberculous Mycobacterial Infections Unmet Needs, KOL’s views, Analyst’s views, Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement

 

Gain a strategic edge in the Nontuberculous Mycobacterial Infections Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Nontuberculous Mycobacterial Infections Market Forecast. Click here to lead in advancements @ Nontuberculous Mycobacterial Infections Clinical Trials Assessment

 

Table of Contents

1. Non- Tuberculous Mycobacterial Infections Market Report Introduction

2. Executive Summary for Non- Tuberculous Mycobacterial Infections

3. SWOT analysis of Non- Tuberculous Mycobacterial Infections

4. Non- Tuberculous Mycobacterial Infections Patient Share (%) Overview at a Glance

5. Non- Tuberculous Mycobacterial Infections Market Overview at a Glance

6. Non- Tuberculous Mycobacterial Infections Disease Background and Overview

7. Non- Tuberculous Mycobacterial Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Non- Tuberculous Mycobacterial Infections

9. Non- Tuberculous Mycobacterial Infections Current Treatment and Medical Practices

10. Non- Tuberculous Mycobacterial Infections Unmet Needs

11. Non- Tuberculous Mycobacterial Infections Emerging Therapies

12. Non- Tuberculous Mycobacterial Infections Market Outlook

13. Country-Wise Non- Tuberculous Mycobacterial Infections Market Analysis (2020–2034)

14. Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement of Therapies

15. Non- Tuberculous Mycobacterial Infections Market Drivers

16. Non- Tuberculous Mycobacterial Infections Market Barriers

17. Non- Tuberculous Mycobacterial Infections Appendix

18. Non- Tuberculous Mycobacterial Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage